Home »  In the Press » PRESS RELEASES 2008 » 2007 » 2006 » 2005 »  2004 »  2003 Tranzyme Pharma Announces Issuance of European Patent Protecting Company’s Novel Macrocyclic Chemistry » December 13, 2006 Tranzyme Pharma Expands Clinical Program of its Novel Ghrelin Agonist, TZP-101, to Include Patients with Gastroparesis » September 21, 2006 Tranzyme Pharma Appoints New Vice President of Business Development & Licensing » August 10, 2006 Tranzyme Pharma Receives Notice of Allowance from USPTO on Patent Protecting Company’s Macrocyclic Chemistry Technology  » July 19, 2006 Tranzyme Pharma Appoints Industry Veteran as Senior Vice President of Research and Preclinical Development » June 21, 2006 Tranzyme Pharma to Present New In Vivo Data on its Novel GI Compounds at Digestive Disease Week 2006 » May 17, 2006 Tranzyme Pharma Announces Successful Completion of Phase I Clinical Trial of its Novel Ghrelin Agonist, TZP-101  » May 10, 2006 Tranzyme Pharma Receives IND Clearance for its Novel Ghrelin Agonist, TZP-101  » January 10, 2006